Condition
Relapsed Lymphomas
Total Trials
1
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
Treatment Research
2 treatments under study, led by Vorinostat
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
100.0%
1 terminated out of 1 trials
Success Rate
0.0%
-86.6% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
1Total
Phase 1/2 (1)
Trial Status
Terminated1
Clinical Trials (1)
Showing 1 of 1 trials
Showing all 1 trials
Research Network
Common Treatments
- Vorinostat1
- Pegylated Liposomal Doxorubicin Pld Doxil1
Active Sponsors
- Merck Sharp & Dohme LLC1
- Yale University1
Top Investigators
Yale University
Related Conditions
- Refractory Lymphomas1